Your browser doesn't support javascript.
loading
Improving anti-cancer drug delivery performance of magnetic mesoporous silica nanocarriers for more efficient colorectal cancer therapy.
Iranpour, Sonia; Bahrami, Ahmad Reza; Nekooei, Sirous; Sh Saljooghi, Amir; Matin, Maryam M.
Afiliación
  • Iranpour S; Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Bahrami AR; Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Nekooei S; Industrial Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Sh Saljooghi A; Department of Radiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Matin MM; Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. saljooghi@um.ac.ir.
J Nanobiotechnology ; 19(1): 314, 2021 Oct 12.
Article en En | MEDLINE | ID: mdl-34641857
ABSTRACT

BACKGROUND:

Improving anti-cancer drug delivery performance can be achieved through designing smart and targeted drug delivery systems (DDSs). For this aim, it is important to evaluate overexpressed biomarkers in the tumor microenvironment (TME) for optimizing DDSs. MATERIALS AND

METHODS:

Herein, we designed a novel DDS based on magnetic mesoporous silica core-shell nanoparticles (SPION@MSNs) in which release of doxorubicin (DOX) at the physiologic pH was blocked with gold gatekeepers. In this platform, we conjugated heterofunctional polyethylene glycol (PEG) onto the outer surface of nanocarriers to increase their biocompatibility. At the final stage, an epithelial cell adhesion molecule (EpCAM) aptamer as an active targeting moiety was covalently attached (Apt-PEG-Au@NPs-DOX) for selective drug delivery to colorectal cancer (CRC) cells. The physicochemical properties of non-targeted and targeted nanocarriers were fully characterized. The anti-cancer activity, cellular internalization, and then the cell death mechanism of prepared nanocarriers were determined and compared in vitro. Finally, tumor inhibitory effects, biodistribution and possible side effects of the nanocarriers were evaluated in immunocompromised C57BL/6 mice bearing human HT-29 tumors.

RESULTS:

Nanocarriers were successfully synthesized with a mean final size diameter of 58.22 ± 8.54 nm. Higher cytotoxicity and cellular uptake of targeted nanocarriers were shown in the EpCAM-positive HT-29 cells as compared to the EpCAM-negative CHO cells, indicating the efficacy of aptamer as a targeting agent. In vivo results in a humanized mouse model showed that targeted nanocarriers could effectively increase DOX accumulation in the tumor site, inhibit tumor growth, and reduce the adverse side effects.

CONCLUSION:

These results suggest that corporation of a magnetic core, gold gatekeeper, PEG and aptamer can strongly improve drug delivery performance and provide a theranostic DDS for efficient CRC therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Portadores de Fármacos / Neoplasias Colorrectales / Dióxido de Silicio / Nanopartículas / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: J Nanobiotechnology Año: 2021 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Portadores de Fármacos / Neoplasias Colorrectales / Dióxido de Silicio / Nanopartículas / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: J Nanobiotechnology Año: 2021 Tipo del documento: Article País de afiliación: Irán